The Efficacy of RS-25259, a Long-Acting Selective 5-HT3 Receptor Antagonist, for Preventing Postoperative Nausea and Vomiting After Hysterectomy Procedures

@article{Tang1998TheEO,
  title={The Efficacy of RS-25259, a Long-Acting Selective 5-HT3 Receptor Antagonist, for Preventing Postoperative Nausea and Vomiting After Hysterectomy Procedures},
  author={Jun Tang and R. D’angelo and P. White and P. Scuderi},
  journal={Anesthesia \& Analgesia},
  year={1998},
  volume={87},
  pages={462-467.}
}
We evaluated the safety and efficacy of RS-25259, a potent and long-acting selective 5-HT3 receptor antagonist, for the prevention of postoperative nausea and vomiting (PONV) in women undergoing hysterectomy procedures. In this randomized, double-blind, placebo controlled, dose-ranging study, 218 healthy, consenting women were assigned to one of the six treatment groups: placebo or RS-25259 0.1, 0.3, 1.0, 3.0, or 30 [micro sign]g/kg. All patients underwent a standardized general anesthetic… Expand
Anti-emetics in development
  • P. Loewen
  • Medicine
  • Expert opinion on investigational drugs
  • 2002
...
1
2
3
...

References

SHOWING 1-10 OF 28 REFERENCES
Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.
...
1
2
3
...